Leadership

We have assembled a seasoned management team. Our leaders have played critical roles in the discovery and advancement of multiple first-in-class oncology therapeutics, from early-stage research through clinical trials, and ultimately to regulatory approval and commercialization, including Kisqali®, Onivyde®, Tafinlar®, Tazverik®, Velcade® and Zolinza®.

Prakash Raman, Ph.D.

President and Chief Executive Officer

Paul Brannelly

Chief Financial Officer

Sally Johnson

Chief People Officer

Heike Keilhack, Ph.D.

Chief Scientific Officer

Kevin Kuntz, Ph.D.

Chief Drug Development Officer

Sudha Parasuraman, M.D.

Chief Medical Officer

Gary Sutton

Chief Business Officer
Join our team of experts.
Find Out More